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BACKGROUND: Neurocognitive decline is a major cause of morbidity in pediatric brain tumor patients. Traditionally, testing to monitor this decline has been completed in a clinic setting. It is often difficult to obtain neurocognitive evaluations in clinic, and testing only in clinics limits the frequency of assessments. Cogstate is a brief computerized neurocognitive battery capable of being administered in unsupervised settings. We administered the Cogstate battery to off therapy brain tumor patients at home and in the clinic to evaluate its utility in monitoring cognition at home. MATERIALS/ METHODS: Demographic data and QOL questionnaires were collected during the in clinic baseline visit, and the Cogstate battery was also completed. A week later, patients completed testing at home. DATA: Twenty-five patients enrolled on study and 19 completed both in clinic and at home assessments. Mean age at diagnosis was 9.8 years, and at study enrollment was 13.0 years. Diagnoses included High Risk Medulloblastoma (n=7), Standard Risk Medulloblastoma (n=1), Ependymoma (n=4), Choroid Plexus Carcinoma (n=1), Ganglioglioma (n=3), Germinoma (n= 1), Nongerminomatous Germ Cell Tumor (n=2), Anaplastic Astrocytoma (n=1), Juvenile Pilocyctic Astrocytoma (n=3), Dysembroplastic Neuroepithelial Tumor (n=1), and Protoplasmic Astrocytoma (n=1). Thirteen patients received chemotherapy and 17 received radiation. All patients successfully completed testing and appeared able to understand the task requirements. No differences were observed between testing done in the clinic and at home. CON-CLUSION: It appears possible to monitor cognition over time on a frequent basis in pediatric brain tumor patients. This has significant implications for clinical trials and clinical medicine. BACKGROUND: Bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor, has been shown in a small series of children with vision loss associated with optic pathway gliomas (OPG) to produce marked vision recovery. METHODS: A single-institution retrospective record review of pediatric patients who had poor visual acuity and received bevacizumab from 2014-2017 was performed at Children's Hospital Colorado. Data collected included demographics, pathology information, visual acuity exams (Snellen), visual field exams, optical coherence tomography (OCT), and bevacizumab dosing and toxicity. RESULTS: Eighteen patients (10:8, male:female) received bevacizumab for poor visual acuity. The median age of patients at the start of bevacizumab treatment was 5.2 years (range, 1.3-21.5 years). Thirteen patients had OPGs, three patients had craniopharyngioma, and two had other brain tumors with vision loss due to hydrocephalus at diagnosis. Median time from tumor diagnosis to start of bevacizumab was 0.6 years (range, 0.1-12.9 years). Most (11/18) patients (8 OPG, 2 craniopharyngioma, 1 glioneuronal tumor) experienced improvement (i.e., LogMAR decrease >0.1) in visual acuity in at least one eye. Bevacizumab (median of 13 doses and range of 4-20 doses administered per patient) was tolerated well overall. Seven patients experienced transient toxicities (including proteinuria, hypertension, and headaches). OCT analysis is ongoing. CONCLUSIONS: Bevacizumab appears to improve visual acuity in some children with vision loss associated with injury to the optic apparatus from tumor or hydrocephalus. A clinical trial to investigate the use of bevacizumab for vision recovery in pediatric brain tumor patients is warranted.
QOL-58. IMPROVEMENT IN VISUAL ACUITY OF PEDIATRIC PATIENTS WITH BRAIN TUMORS WITH BEVACIZUMAB

QOL-59. THE DEVELOPMENT OF A SCHOOL 'BRAIN AID KIT' BOX
Jade Ryles, Faye Fraser, Simon Bailey, and Gail Halliday; Newcastle upon Tyne, Newcastle, UK The purpose of developing the school 'Brain Aid Kit' box (school BAK box) was to empower neuro-oncology patients and their families in survivorship. Within the North East of England, a multi-disciplinary school meeting takes place at diagnosis, relapse and transition in education only. A questionnaire was sent to twenty schools and parents who had received previous school meeting input. The results identified there was a need for education staff to have support and up to date health information at the start of each school year. It is unachievable for professionals to complete a school meeting each school year for every patient in survivorship. Three workshops took place where the information included in the school 'BAK' box was created. Both written and visual information on diagnosis, treatment and side effects, which can be individualised for each patient was added. The information is given in a plain box for patients to decorate, promoting ownership. The school 'BAK' box is being trialled in forty schools within the North East of England, with questionnaire feedback from both schools and parents. All questionnaires will be collated by May 2018, with the aim to offer a school 'BAK' box to every neuro-oncology patient. Preliminary feedback has indicated families have been able to information share appropriate and key information with their schools confidently and competently. There is currently no other known tool across England that addresses on-going issues of education in survivorship within the neuro-oncology services. The hope is the school 'BAK' box will fill this void.
QOL-60. PANACEA: A NOVEL BLACKBERRY 10 BASED, SUPPORT MOBILE APP FOR BRAIN TUMOR AFFECTED PATIENTS.
Abhishek Puri 1 , Amit Garg 1 , and P Mohandass 1 ; 1 Fortis Cancer Institute, Mohali, Punjab, India, 2 Hugsoft Inc., Mohali, Pujab, India Panacea addresses a yawning gap in clinician-led development for novel use of mobile applications in healthcare delivery for patients. METHODS: Brain tumour affected patients have difficulty in accessing relevant literature to their clinical condition and reminders for medications. A novel BlackBerry 10 mobile app, Panacea, (final version 1.1.9.1) was conceptualised and developed (using C++ and BlackBerry 10 native SDK) available via BlackBerry World. BlackBerry 10 (OS version 10.3.2.2826) offers a platform with NIAP certification, which ratifies it for security allowing for unrestricted use for regulated healthcare. This app has news section (for patient advocacy), reminders to aid in dispensing of critical medications, ability to add emergency contacts and clinician vetted information for managing common side effects, primarily related to concurrent chemo-radiation therapy. This app also allows for visual theming, reader mode to enhance the readability of web content and sharing of news through various social media. Panacea is securely linked to installed BlackBerry Messenger (BBM), for instant messaging which also allows voice and video interaction with the clinical specialist. Future updates include enhanced heuristics (UI design with emphasis on the visual component), interface with hospital-based information systems, daily log of symptoms experienced and integration with chatbots for measured automated responses to repetitive queries. Porting to Android and Apple iOS platform is being contemplated. Panacea aims to transform information access with clinician vetting to aid in ownership of healthcare, functional independence and remote monitoring of patients.
